Mandate

Vinge advises Trill Impact and ID North in connection with the acquisition of Pulsen Integration's IAM business

Vinge advises Trill Impact and its portfolio company ID North in connection with the acquisition of Pulsen Integration's Identity Access Management (IAM) business.

In total, 35 employees from Pulsen Integration in Sweden and Finland will become part of ID North, which operates within IAM and cyber security, providing IT consulting services, resale and in-house development of IT products with its base in Stockholm. At the same time, Pulsen Group becomes a shareholder in the parent company European ID Security, which includes ID North and Arctic Group. After the transaction, ID North consists of 65 employees in Sweden and Finland.

Vinge's team mainly consisted of Christina Kokko, Matthias Pannier, Samra Baytar, Nina Gransäter, Linus Adolfsson (M&A), Isabell Nielsen, Jolene Reimerson, Lisa Hörnqvist, Karolina Fuhrman (Commercial Agreements, IT & GDPR), Åsa Gotthardsson, Emil Lindwall (Employment), Arvid Axelryd (IP), Frida Ställborn (Real Property), Ulf Pyk (Banking and Finance), Ellinore Boström Andersson and Ellinor Gyllenhammar (Project Assistants).

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026